News und Analysen
Why CRISPR Therapeutics Stock Charged Northward This Week
Gene therapy stocks have been a bright spot in the market this week. For instance, gene correction specialist CRISPR Therapeutics (NASDAQ: CRSP) has so far gained 19.6% through the first four days
Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA
On Oct. 31, Vertex Pharmaceuticals (NASDAQ: VRTX) and its collaborator CRISPR Therapeutics (NASDAQ: CRSP) met with regulators at the Food and Drug Administration (FDA) in a high-stakes meeting about
Is AbbVie Stock a Buy Now?
With its diluted earnings per share (EPS) collapsing by nearly 55% in the third quarter to reach $1, it's easy to see why now might not seem like a good time to buy AbbVie (NYSE: ABBV) stock. To
There's a Silver Lining in Pfizer's Dark Cloud. Should You Buy the Stock?
It may seem difficult to get excited about Pfizer (NYSE: PFE) these days. After the company brought in record revenue of $100 billion last year thanks to its coronavirus vaccine, Comirnaty, and its
Zoetis (ZTS) Q3 2023 Earnings Call Transcript
Cigna Group (CI) Q3 2023 Earnings Call Transcript
1 Stock Down 15% This Year to Buy and Hold Forever
The past three years have been a roller coaster for Abbott Laboratories (NYSE: ABT). The healthcare giant dealt with a slowdown in its medical device business caused by the pandemic, fluctuating
This High-Yield Dividend Stock Is a Proven Wealth Creator
Found in 1849, Pfizer (NYSE: PFE) has transformed the lives of patients and shareholders alike. The pharmaceutical titan has been one of the best-performing stocks since the end of World War II
3 Dividend Stocks That Can Power Your Portfolio for Decades
Holding some top dividend stocks in your portfolio can help you generate recurring income for years. This can bolster your savings for retirement or just give you extra money to help pay bills while
1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years
The pharmaceutical industry has been a source of extraordinary returns for investors who have picked the right stocks. Since the end of World War II, five of the top 30 performers in the U.S. stock
One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics?
CRISPR Therapeutics (NASDAQ: CRSP) has reached a very important chapter in its growth story. The gene-editing specialist doesn't have products on the market right now, but that could change in just
Pfizer Posted a Steep Loss. Is It Time to Sell?
It's been about a couple of weeks since Pfizer (NYSE: PFE) promised to make Halloween extra spooky by warning us that third-quarter results would be disappointing.
It turns out the warning was more
Pfizer (PFE) Q3 2023 Earnings Call Transcript
Pfizer's Coming for AbbVie's Market Share. Here's What It Means for Investors
On Oct. 13, regulators at the Food and Drug Administration (FDA) ruled that Pfizer's (NYSE: PFE) new drug for moderate to severe ulcerative colitis (UC), Velsipity, was ready for prime time. That
Humana Repeats as U.S. News & World Report’s Best Overall Medicare Advantage Plan Company for Second Year in a Row
For the second year in a row, U.S. News & World Report recognized leading health and well-being company Humana Inc. (NYSE: HUM) as the 2024 Best Insurance Company for Medicare Advantage in three
Investing $1,000 in These 2 Top Stocks Would Be a Brilliant Move
There are many things you can buy with $1,000, but most won't multiply your wealth over time. Investing in equity markets remains one of the best options. Buying shares of great companies and
Is AbbVie Still a Good Dividend Stock to Buy?
One thing income seekers don't want to see from the businesses they invest in is a major disruption to their incoming cash flows. Unfortunately for shareholders of AbbVie (NYSE: ABBV), the
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
As you may have heard, Novo Nordisk (NYSE: NVO) makes Ozempic, the type 2 diabetes medication sweeping the globe and raking in billions in the process. Where there's a money-printing drug in ascent
Why AbbVie Stock Was a Winner on Monday
Pharmaceutical company AbbVie (NYSE: ABBV) was a cure for the investor blues on Monday. Shares of the company rose more than 2% in price on an analyst's recommendation upgrade. AbbVie stock's
Why Revvity Stock Plunged Today
Shares of Revvity (NYSE: RVTY) -- formerly known as PerkinElmer -- fell 16.1% on Monday after the health science solutions and services company announced weaker-than-expected third-quarter 2023
2 No-Brainer Dividend Stocks to Buy This Week
Dividend stocks can be consistent market-beaters. However, empirical research shows that the best dividend stocks tend to generate better-than-average returns because of their underlying value
Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade
Sometimes, the old financial adages are spot on. For example, it does take money to make money. And the expression that "time is money" is correct in many ways.
But it's also true that some
Why AbbVie Stock Fell Today
Shares of AbbVie (NYSE: ABBV) were down 5.4% as of 2:00 p.m. ET Friday, even after the pharmaceuticals giant announced slightly better-than-expected quarterly results and raised its full-year
AbbVie (ABBV) Q3 2023 Earnings Call Transcript
Beat the Dow Jones With UnitedHealth Group Stock
If you want to beat the market, the key is having strong stocks in your portfolio of businesses that are profitable and growing. One name that has routinely outperformed the markets is health